Tardive Dyskinesia Treatment Market Research Report: By Treatment Type (Antipsychotic Medications, Cholinergic Agents, GABAergic Agents, Glutamatergic Agents, Botulinum Toxin Injections), By Disease Severity (Mild, Moderate, Severe), By Treatment Setting (Inpatient, Outpatient, Home Healthcare), By End-User (Patients, Caregivers, Hospitals, Clinics, Pharmacies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Global Tardive Dyskinesia Treatment Market Overview

As per MRFR analysis, the Tardive Dyskinesia Treatment Market Size was estimated at 3.55 (USD Billion) in 2022.

The Tardive Dyskinesia Treatment Market Industry is expected to grow from 3.82(USD Billion) in 2023 to 7.52 (USD Billion) by 2032. The Tardive Dyskinesia Treatment Market CAGR (growth rate) is expected to be around 7.81% during the forecast period (2024 - 2032).

Key Tardive Dyskinesia Treatment Market Trends Highlighted

The Tardive Dyskinesia Treatment Market is characterized by the rising prevalence of tardive dyskinesia, primarily induced by the prolonged use of antipsychotics. The increasing awareness of the condition and the unmet medical needs drive the demand for effective treatments.Technological advancements have led to the development of novel therapies, including gene editing techniques and neuromodulation devices, offering new avenues for symptom management. The market is further influenced by government initiatives and research collaborations aimed at improving patient outcomes.Recent trends indicate a shift towards personalized medicine, with tailored treatments based on individual patient profiles and genetic factors. Additionally, there is a growing emphasis on early diagnosis and intervention, recognizing the importance of prompt treatment to prevent irreversible damage.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Tardive Dyskinesia Treatment Market Drivers

Rising Prevalence of Tardive Dyskinesia

Tardive dyskinesia (TD) is a movement disorder that can develop in individuals who take certain medications for an extended period of time, particularly antipsychotics. The prevalence of TD is increasing globally due to several factors, including the aging population, increased use of antipsychotics and better recognition of the condition. The growing number of TD cases is driving the demand for effective treatment options, contributing to the growth of the Tardive Dyskinesia Treatment Market Industry.

Advancements in Treatment Approaches

The Tardive Dyskinesia Treatment Market Industry is witnessing substantial progression in the treatment of the disease. The researchers are focusing on discovering new pharmacological and non-pharmacological interventions to treat TD. Several therapies, such as deep brain stimulation, transcranial magnetic stimulation, and gene therapy, have been discovered, and many new are in the pipeline which is expected to increase the treatment options for patients and the market growth.

Growing Awareness and Patient Advocacy

Increased awareness about TD among healthcare professionals and patients is contributing to the growth of the Tardive Dyskinesia Treatment Market Industry. Patient advocacy groups are playing a crucial role in educating the public about TD, promoting early diagnosis, and advocating for improved access to treatment. The growing awareness and patient advocacy efforts are creating a more favorable environment for the development and commercialization of effective TD treatments.

Tardive Dyskinesia Treatment Market Segment Insights

Tardive Dyskinesia Treatment Market Treatment Type Insights

The Tardive Dyskinesia Treatment Market is segmented by Treatment Type as Antipsychotic Medications, Cholinergic Agents, GABAergic Agents, Glutamatergic Agents, and Botulinum Toxin Injections. Antipsychotic Medications dominated the Tardive Dyskinesia Treatment Market, with more than 50% market share. This can be primarily attributed to the fact that Antipsychotic Medications are the first line of treatment. The Cholinergic Agents are expected to grow significantly during the forecast period because they are more potent than the existing medications in improving motor symptoms.GABAergic Agents and Glutamatergic Agents are also getting attention in the ongoing research to establish their role in subduing the symptoms of Tardive Dyskinesia. This is mainly attributed to the increasing prevalence of the disorder, rising awareness about the condition, and evolving treatment modalities. The market is also expected to be catalyzed by the growing geriatric population because Tardive Dyskinesia is primarily witnessed among them. Future developments can also revolve around the advent of safe and potent medications with minimal side effects and the use of stem cells to modulate the condition.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Tardive Dyskinesia Treatment Market Disease Severity Insights

The Tardive Dyskinesia Treatment Market is segmented by disease severity into mild, moderate, and severe. Among these, the moderate segment is expected to hold the largest market share of around 42.7% by 2023. This is because moderate TD is the most common type, affecting an estimated 50% of the patients with TD. The mild segment is expected to be growing at the CAGR of 8.5% during the forecast period, as the timely detection and treatment of TD can enhance the treatment outcome. The severe segment is expected to occupy a market share of around 27.3% by 2023, as it requires intensive care and is highly prone to complications.

Tardive Dyskinesia Treatment Market Treatment Setting Insights

Outpatient settings are expected to dominate the Tardive Dyskinesia Treatment Market, accounting for a revenue share of over 55% in 2024. The growing preference for outpatient care due to its convenience, lower costs, and advancements in medication administration techniques are driving this segment's growth. Home healthcare is also expected to witness significant growth, primarily driven by the increasing geriatric population and the rising demand for home-based care services. Inpatient settings, while having a smaller market share, play a crucial role in managing severe cases of tardive dyskinesia and providing intensive care and support.

Tardive Dyskinesia Treatment Market End-User Insights

The Tardive Dyskinesia Treatment Market can be segmented based on end-users, with the major segments being patients, caregivers, hospitals, clinics and pharmacies. The largest segment in terms of revenue is hospitals, which accounted for over 50% of the global market in 2023. This is due to the fact that hospitals are the primary setting for the diagnosis and treatment of tardive dyskinesia. Clinics are the second largest segment, followed by pharmacies. The patient segment is expected to grow at the highest CAGR over the forecast period, as the increasing prevalence of tardive dyskinesia is leading to a greater demand for treatment.

Tardive Dyskinesia Treatment Market Regional Insights

The regional segmentation of the Tardive Dyskinesia Treatment Market offers valuable insights into the distribution of market share and growth opportunities across key regions. North America is projected to maintain its dominance, capturing a significant share of the market revenue in 2023. This dominance is primarily driven by factors such as the high prevalence of mental health disorders, established healthcare infrastructure, and ongoing research and development activities in the region. Europe follows closely behind, with a substantial market share and increasing adoption of novel therapies.The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, fueled by rising healthcare expenditure, growing awareness of tardive dyskinesia, and increasing access to medical facilities. South America and the Middle East and Africa (MEA) regions are also anticipated to contribute to the overall market growth, albeit at a slower pace.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Tardive Dyskinesia Treatment Market Key Players And Competitive Insights

The Tardive Dyskinesia Treatment Market is a dynamic and competitive landscape with a diverse range of players. Key industry leaders include AbbVie, Allergan, Neurocrine Biosciences, Teva Pharmaceutical Industries, and Sunovion Pharmaceuticals. These companies hold a significant market share and drive innovation in the development and commercialization of Tardive Dyskinesia treatments. The Tardive Dyskinesia Treatment Market has witnessed strategic partnerships, mergers and acquisitions, and collaborations among players to expand their portfolios and gain a competitive edge.Leading Tardive Dyskinesia Treatment Market PlayersAbbVieAbbVie is a global biopharmaceutical company headquartered in the United States. The company has a strong presence in the Tardive Dyskinesia Treatment Market with its blockbuster drug, Depakote (valproic acid). Depakote is a widely prescribed medication for the treatment of seizures and bipolar disorder and has also been shown to reduce symptoms of Tardive Dyskinesia. AbbVie's focus on research and development has led to the expansion of its Tardive Dyskinesia Treatment portfolio with the development of newer and more effective therapies.Competitor companyAllerganAllergan is an American pharmaceutical company specializing in ophthalmology, dermatology, medical aesthetics, and neurology. The company's involvement in the Tardive Dyskinesia Treatment Market stems from its expertise in neurology. Allergan's key Tardive Dyskinesia Treatment product is Botox (onabotulinumtoxinA), a neuromodulator used for treating a range of neurological disorders. Allergan has been actively engaged in clinical trials and research to evaluate the efficacy and safety of Botox in managing Tardive Dyskinesia symptoms. The company's commitment to innovation and patient care positions it as a formidable competitor in the Tardive Dyskinesia Treatment Market.

Key Companies in the Tardive Dyskinesia Treatment Market Include

• Teva


• Amneal


• Sun Pharmaceutical Industries


• Apotex


• Mylan


• Reddy's Laboratories


• Actavis


• Cadila Healthcare


• Glenmark Pharmaceuticals


• Torrent Pharmaceuticals


• Abbott


• Lupin


• Sandoz


• Cipla

Tardive Dyskinesia Treatment Market Industry Developments

The Tardive Dyskinesia Treatment Market is expected to grow significantly over the forecast period, driven by the rising prevalence of tardive dyskinesia and the increasing demand for effective treatments. In 2023, the market was valued at USD 3.82 billion and is projected to reach USD 7.52 billion by 2032, exhibiting a CAGR of 7.81%. Key factors contributing to market growth include the growing geriatric population, the increasing use of antipsychotic medications, and the rising awareness of tardive dyskinesia. Moreover, the development of novel therapies and the expansion of treatment options are anticipated to further propel market growth.

Tardive Dyskinesia Treatment Market Segmentation Insights

Tardive Dyskinesia Treatment Market Treatment Type Outlook

• Antipsychotic Medications


• Cholinergic Agents


• GABAergic Agents


• Glutamatergic Agents


• Botulinum Toxin Injections

Tardive Dyskinesia Treatment Market Disease Severity Outlook

• Mild


• Moderate


• Severe

Tardive Dyskinesia Treatment Market Treatment Setting Outlook

• Inpatient


• Outpatient


• Home Healthcare

Tardive Dyskinesia Treatment Market End-User Outlook

• Patients


• Caregivers


• Hospitals


• Clinics


• Pharmacies

Tardive Dyskinesia Treatment Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa